Independent Association of Hypovitaminosis D with Non-alcoholic Fatty Liver Disease in People with Chronic Spinal Cord Injury: a Cross-sectional Study

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2023 Jun 5

PMID 37273143

Authors

F Di Giulio

C Castellini

D Tienforti

G Felzani

M G Baroni

A Barbonetti

Affiliations

Soon will be listed here.

Abstract

Purpose: Non-alcoholic fatty liver disease (NAFLD) and hypovitaminosis D are highly prevalent in people with spinal cord injury (SCI) and could exert an unfavorable influence on cardiovascular profile and rehabilitation outcomes. We aimed to assess the independent association between low 25-hydroxy vitamin D (25(OH)D) levels and NAFLD in people with chronic (> 1 year) SCI.

Methods: One hundred seventy-three consecutive patients with chronic SCI (132 men and 41 women) admitted to a rehabilitation program underwent clinical/biochemical evaluations and liver ultrasonography.

Results: NAFLD was found in 105 patients (60.7% of the study population). They were significantly older and exhibited a poorer leisure time physical activity (LTPA) and functional independence in activities of daily living, a greater number of comorbidities and a higher prevalence of metabolic syndrome (MetS) and its correlates, including lower HDL and higher values of body mass index (BMI), systolic blood pressure, HOMA-index of insulin resistance and triglycerides. 25(OH)D levels were significantly lower in NAFLD (median: 10.6 ng/ml, range: 2.0-31.0) than in non-NAFLD group (22.5 ng/ml, 4.2-51.6). When all these variables were included in a multiple logistic regression analysis, a significant independent association with NAFLD only persisted for lower 25(OH)D levels, a greater number of comorbidities and a poorer LTPA. The ROC analysis revealed that 25(OH)D levels < 18.25 ng/ml discriminated patients with NAFLD with a sensitivity of 89.0% and a specificity of 73.0% (AUC: 85.7%; 95%CI: 79.6-91.7%). NAFLD was exhibited by 83.9% of patients with 25(OH)D levels < 18.25 ng/ml and by 18% of those with 25(OH)D levels ≥ 18.25 ng/ml (p < 0.0001).

Conclusion: In people with chronic SCI, 25(OH)D levels < 18.25 ng/ml may represent a marker of NAFLD independent of MetS-related features. Further studies are warranted to define the cause-effect relationships of this association.

Citing Articles

Correlates of metabolic syndrome in people with chronic spinal cord injury.

Di Giulio F, Castellini C, Palazzi S, Tienforti D, Antolini F, Felzani G J Endocrinol Invest. 2024; 47(8):2097-2105.

PMID: 38285309 PMC: 11266227. DOI: 10.1007/s40618-023-02298-8.

References

Angulo P, Lindor K . Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002; 17 Suppl:S186-90. DOI: 10.1046/j.1440-1746.17.s1.10.x. View

Medina J, Fernandez-Salazar L, Garcia-Buey L, Moreno-Otero R . Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004; 27(8):2057-66. DOI: 10.2337/diacare.27.8.2057. View

Targher G, Day C, Bonora E . Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363(14):1341-50. DOI: 10.1056/NEJMra0912063. View

Kotronen A, Yki-Jarvinen H . Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007; 28(1):27-38. DOI: 10.1161/ATVBAHA.107.147538. View

Lee D, Tajar A, ONeill T, OConnor D, Bartfai G, Boonen S . Lower vitamin D levels are associated with depression among community-dwelling European men. J Psychopharmacol. 2010; 25(10):1320-8. DOI: 10.1177/0269881110379287. View

Barbonetti A, Cavallo F, DAndrea S, Muselli M, Felzani G, Francavilla S . Lower Vitamin D Levels Are Associated With Depression in People With Chronic Spinal Cord Injury. Arch Phys Med Rehabil. 2016; 98(5):940-946. DOI: 10.1016/j.apmr.2016.11.006. View

Pilz S, Tomaschitz A, Ritz E, Pieber T . Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol. 2009; 6(10):621-30. DOI: 10.1038/nrcardio.2009.135. View

Pittas A, Lau J, Hu F, Dawson-Hughes B . The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007; 92(6):2017-29. PMC: 2085234. DOI: 10.1210/jc.2007-0298. View

Forouhi N, Luan J, Cooper A, Boucher B, Wareham N . Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes. 2008; 57(10):2619-25. PMC: 2551670. DOI: 10.2337/db08-0593. View

10.

Illescas-Montes R, Melguizo-Rodriguez L, Ruiz C, Costela-Ruiz V . Vitamin D and autoimmune diseases. Life Sci. 2019; 233:116744. DOI: 10.1016/j.lfs.2019.116744. View

11.

Barbonetti A, Vassallo M, Felzani G, Francavilla S, Francavilla F . Association between 25(OH)-vitamin D and testosterone levels: Evidence from men with chronic spinal cord injury. J Spinal Cord Med. 2015; 39(3):246-52. PMC: 5073757. DOI: 10.1179/2045772315Y.0000000050. View

12.

Wicherts I, van Schoor N, Boeke A, Visser M, Deeg D, Smit J . Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab. 2007; 92(6):2058-65. DOI: 10.1210/jc.2006-1525. View

13.

Barbonetti A, Sperandio A, Micillo A, DAndrea S, Pacca F, Felzani G . Independent Association of Vitamin D With Physical Function in People With Chronic Spinal Cord Injury. Arch Phys Med Rehabil. 2016; 97(5):726-32. DOI: 10.1016/j.apmr.2016.01.002. View

14.

Barbonetti A, DAndrea S, Martorella A, Felzani G, Francavilla S, Francavilla F . Low vitamin D levels are independent predictors of 1-year worsening in physical function in people with chronic spinal cord injury: a longitudinal study. Spinal Cord. 2018; 56(5):494-501. DOI: 10.1038/s41393-017-0058-7. View

15.

Wortsman J, Matsuoka L, Chen T, Lu Z, Holick M . Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000; 72(3):690-3. DOI: 10.1093/ajcn/72.3.690. View

16.

Sato M, Hiragun A . Demonstration of 1 alpha,25-dihydroxyvitamin D3 receptor-like molecule in ST 13 and 3T3 L1 preadipocytes and its inhibitory effects on preadipocyte differentiation. J Cell Physiol. 1988; 135(3):545-50. DOI: 10.1002/jcp.1041350326. View

17.

Barchetta I, Cimini F, Cavallo M . Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. Nutrients. 2020; 12(11). PMC: 7693133. DOI: 10.3390/nu12113302. View

18.

Barchetta I, Cimini F, Chiappetta C, Bertoccini L, Ceccarelli V, Capoccia D . Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. Liver Int. 2020; 40(9):2139-2147. DOI: 10.1111/liv.14554. View

19.

Wood R . Vitamin D and adipogenesis: new molecular insights. Nutr Rev. 2008; 66(1):40-6. DOI: 10.1111/j.1753-4887.2007.00004.x. View

20.

Kong J, Li Y . Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab. 2005; 290(5):E916-24. DOI: 10.1152/ajpendo.00410.2005. View